Background
Broadly neutralizing antibodies (bNAbs) are currently being evaluated in clinical trials for HIV treatment and cure as immunomodulatory alternatives to standard antiretroviral therapy (ART). Existing methods are insufficient to accurately predict bNAb sensitivity of HIV-1 in vivo, especially for ART-treated individuals. In pursuit of a rapid, sensitive, and scalable pre-screening method, we report the development of a co-culture-based combined viral outgrowth and neutralization assay to quantify bNAb sensitivity of HIV-1 reactivated from PBMCs.
Methods
CD4+ T cells from people living with HIV (PLWH) were treated ex vivo with a cocktail of synergistic LRAs including panobinostat and lipid nanoparticle (LNP)-delivered HIV-1 Tat mRNA to reactivate HIV-1 provirus following TCR activation. These “donor” cells were then co-cultured with RevCEM-based indicator “target” cells (RevCEM-GNL-S7) in a 96-well plate format (1×105 each CD4+ and RevCEM-GNL-S7 cells/well). Co-cultured cells were monitored for outgrowth by flow cytometry. Upon detection of outgrowth, cells were subjected to a secondary co-culture with fresh RevCEM-GNL-S7 target cells in the presence of the bNAb 10-1074 to assess sensitivity of outgrown virus to neutralization.
Results
From 9 PLWH (3 viremic and 6 suppressed), we isolated 6×105 – 9×106 CD4+ T cells. We achieved successful HIV-1 outgrowth from 100% of participants. Detectable outgrowth was observed in an average of 91.7% of LRA-treated wells from viremic PLWH and 17.1% of such wells from suppressed PLWH following 10 days of co-culture. Sufficient outgrowth was detected from all participants within two weeks of sample collection to assay for neutralization by 10-1074 and establish IC50 values and/or maximum percent inhibition (MPI) for each participant. Neutralization by 10-1074 (IC50 < 2 µg/mL or MPI > 90%) was observed in 3/8 tested participants.
Conclusions
Leveraging a sensitive cell-reporter neutralization assay, LRA synergy, and flow cytometry-based detection methods, we have developed a rapid and sensitive single-cell viral outgrowth and neutralization assay that addresses several challenges to accurate screening for bNAb sensitivity in the HIV-1 latent reservoir. This assay presents a novel method to efficiently screen viremic and virologically suppressed PLWH for bNAb susceptibility, with the potential to improve efficiency of bNAb clinical development.